|
Please review some of our latest thinking on the pharmaceuticals and medical products industries.
(Please note: free, one-time registration is required to read any McKinsey Quarterly articles listed on this page).
 |  | | Generics and Big Pharma | | August 2006
The time ripe for pharmaceutical companies to reexamine their relationships with generic drug manufacturers and find new ways to work together. Given the challenges facing the industry, identifying alternative opportunities are critical to driving revenue and profitable growth. | Learn more (PDF - 327 KB ) |
|
| | | Why Products Fail in Phase III | | April 2006
Half of the small-molecule drugs that fail pivotal trials can't prove better efficacy than placebos. The most important predictor of failure: a drug with a novel mechanism of action. But for the most part, companies pursuing a one-size-fits all development strategy, using the same methods for developing drugs that modulate novel and precedented targets. Companies need to better differentiate their development strategies based on risk. | | Learn more (PDF - 66 KB) |
|
| | | Avian flu: Expanding global vaccine production | | Web exclusive, July 2006
If governments are to be prepared for a potential avian-flu pandemic, they must bring pharmaceutical companies and health organizations into the strategic-planning process. | Read more on the McKinsey Quarterly site |
|
| | | Improving the Pharma Research Pipeline | | The McKinsey Quarterly, 2004 Web exclusive
Pharma companies should reassess their mix of internally and externally developed products.
| | Read more on the McKinsey Quarterly site |
|
| | | Making Pharma Alliances Work | | The McKinsey Quarterly, 2004 Number 1
As joint ventures become more complex, a division of labor is sometimes the key to successful partnerships. | | Read more on the McKinsey Quarterly site |
|
| | | Pharma for Fido | | The McKinsey Quarterly, 2003 Number 2
The animal health industry will grow steadily over the next several years, providing solid if unspectacular profits for the pharma companies that own most of the businesses in it—but may now wish to divest them.
| | Read more on the McKinsey Quarterly site |
|
| | | A Cure for Clinical Trials | | The McKinsey Quarterly, 2002 Number 2
U.S. pharma companies often miss their deadlines when testing new drugs. The use of marketing techniques to manage the recruitment of patients for clinical trials could speed things up considerably. | | Read more on the McKinsey Quarterly site |
|
| | | Pharma Goes Direct in Japan | | The McKinsey Quarterly, 2003 Number 2
Despite restrictions on drug advertising in Japan, recent pilot campaigns suggest new ways for companies to reach out to patients. | | Read more on the McKinsey Quarterly site |
|
| | | Making More of Pharma's Sales Force | | The McKinsey Quarterly, 2002 Number 3
Pharmaceutical companies have lost their focus on doctors. The key to higher sales is regaining it. | | Read more on the McKinsey Quarterly site |
|
| | | The New Math for Drug Licensing | | The McKinsey Quarterly, 2002 Number 4
Pharmaceutical companies that license drugs too late are losing out on significant amounts of value. | | Read more on the McKinsey Quarterly site |
|
|
|
|
|
| | Pharmaceuticals & Medical Products Practice | |
 | Latest Thinking | |
| Contact Information | |
| |
|
|
